'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale [Seeking Alpha]
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Seeking Alpha
Investing Experts Podcast 6.59K Follower s Subscribe Summary Cybin's CYB003 and CYB004 programs show promising results in treating depression and anxiety, with CYB003 achieving 75% remission in Phase 2 trials. Phase 3 trials, leveraging a strong IP portfolio and a streamlined operational structure. Despite recent stock pressure, do Cybin's financials and upcoming data catalysts present a compelling investment opportunity? thiago melo/iStock via Getty Images Listen here or on the go via Apple Podcasts and Spotify Cybin ( NYSE: CYBN NEOE: CYBN:CA ) CEO Doug Drysdale talks to Jason Najum about transforming treatment of mental health disorders with psychedelics (0:45). CYB003, Phase 2 results for depression, moving into Phase 3 (3:00). How deuterated psilocin differentiates Cybin from competition (10:00). IP and patents - critical to ROI (12:45). Esketamine and is ( JNJ )'s Spravato blazing a trail for psychedelics? (14:15) FDA challenges and Lykos lessons (21:20). Stro
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics” [Yahoo! Finance]Yahoo! Finance
- Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry SummitBusiness Wire
- Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $114.00 to $96.00. They now have a "buy" rating on the stock.MarketBeat
- Cybin Provides Corporate Update on Upcoming Clinical Milestones [Yahoo! Finance]Yahoo! Finance
- Cybin Provides Corporate Update on Upcoming Clinical MilestonesBusiness Wire
CYBN
Earnings
- 6/26/24 - Miss
CYBN
Sec Filings
- 9/24/24 - Form 6-K
- 9/20/24 - Form 6-K
- 9/20/24 - Form 6-K
- CYBN's page on the SEC website